KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Moderate Buy” from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given an average rating of “Moderate Buy” by the ten analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $26.4286.

A number of research firms have commented on KALV. HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. JMP Securities lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Friday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Finally, Leerink Partners upped their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, July 7th.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $10.91 on Friday. The company has a fifty day moving average price of $12.63 and a two-hundred day moving average price of $12.87. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $17.28. The stock has a market cap of $551.21 million, a price-to-earnings ratio of -2.77 and a beta of -0.15.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The business had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.97 million. Research analysts anticipate that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 10,940 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $144,626.80. Following the transaction, the chief executive officer directly owned 386,858 shares in the company, valued at approximately $5,114,262.76. This represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul K. Audhya sold 2,942 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider owned 119,841 shares in the company, valued at $1,584,298.02. This trade represents a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 26,856 shares of company stock worth $374,910 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Emerald Mutual Fund Advisers Trust lifted its position in KalVista Pharmaceuticals by 19.4% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock worth $11,181,000 after purchasing an additional 149,003 shares during the period. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after acquiring an additional 313,205 shares during the last quarter. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $57,000. SG Americas Securities LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $507,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $63,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).